0.00
前日終値:
$2.27
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$227.15M
収益:
-
当期純損益:
$-299.80M
株価収益率:
0.00
EPS:
-2.84
ネットキャッシュフロー:
$-217.49M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
Acelyrin Inc Stock (SLRN) Company Profile
SLRN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SLRN
Acelyrin Inc
|
0.00 | 227.15M | 0 | -299.80M | -217.49M | -2.84 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-07-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | 開始されました | Wells Fargo | Equal Weight |
2023-12-08 | 開始されました | Citigroup | Neutral |
2023-09-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-09-05 | 開始されました | H.C. Wainwright | Buy |
2023-05-30 | 開始されました | Jefferies | Buy |
2023-05-30 | 開始されました | Morgan Stanley | Overweight |
2023-05-30 | 開始されました | Piper Sandler | Overweight |
2023-05-30 | 開始されました | TD Cowen | Outperform |
すべてを表示
Acelyrin Inc (SLRN) 最新ニュース
Acelyrin Requests to Dismiss Class Action Filed by Investors - TradingView
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com
Jane Street Group LLC Lowers Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Bank of America Corp DE - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Two Sigma Advisers LP - Defense World
Wellington Management Group LLP Invests $567,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
ProShare Advisors LLC Purchases 5,617 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Deutsche Bank AG - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ameriprise Financial Inc. - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
BNP Paribas Financial Markets Invests $236,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Northern Trust Corp Grows Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P TMI Index - marketscreener.com
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P Global BMI Index - marketscreener.com
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
Dimensional Fund Advisors LP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
Alumis-ACELYRIN Merger Gets Green Light: Major Breakthrough for Immune Disease Treatment Pipeline - Stock Titan
Hsbc Holdings PLC Makes New $36,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (SLRN) Projected to Post Earnings on Tuesday - Defense World
Barclays PLC Increases Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Wells Fargo & Company MN Grows Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin Inc (SLRN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):